Tekcapital plc, (AIM: TEK) has revealed a new report in which Grand View Research estimates global medical sales of portable oxygen concentrators and cylinders.
Tekcapital owns 18.9% of the share capital of Belluscura, which is currently awaiting FDA clearance for its first portable oxygen concentrator, the X-PLO2RTM.
FDA clearance is currently anticipated in H1 2020.
Impact of COVID-19
Amongst other factors, the report examines the impact of new data from the COVID-19 pandemic on market demand and anticipates unit sales to grow from 405k units per year in 2019 to 581k units per year in 2026 for a total value of $1.4bn.
Reduced Lung Function
Additionally, a new study indicates recovered COVID-19 patients can be left with damaged lungs, which may require further oxygen treatment. Further investigations of the recovered COVID-19 patients must now be conducted to show whether they have developed pulmonary fibrosis - scarring in the lungs2.
According to Tekcapital director Robert Miller, M.D., "A portion of the patients who recover from COVID-19 may present residual lung damage, necessitating the use of supplemental oxygen."
References
1 https://drive.google.com/file/d/1s5Ou0UQWwjUfWAZ4TNcVMAtsBivvH9r5/view
2 https://www.dw.com/en/covid-19-recovered-patients-have-partially-reduced-lung-function/a-52859671